MedTrace Logo

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

NCT03504956 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-08-14

No results posted yet for this study

Summary

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.

Conditions

  • Coronary Atherosclerosis

Interventions

DEVICE

Cardiac MRI

MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.

DRUG

Contrast

The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).

DRUG

Beta blocker

Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Debiao Li, PhD · Cedars-Sinai Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-30
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03504956 on ClinicalTrials.gov